In Re Hospitalization of B.
This text of 383 A.2d 760 (In Re Hospitalization of B.) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
IN THE MATTER OF THE HOSPITALIZATION OF B.
Superior Court of New Jersey, Law Division.
*232 Mr. Donald T. Smith, Union County Legal Services Corporation, for patient.
Mr. William F. Hyland, Attorney General, for Department of Human Services (Mr. Steven Wallach, Deputy Attorney General, appearing).
Mr. Anthony Russo, Union County Adjuster, for County of Union.
CALLAHAN, J.D.C., Temporarily Assigned.
The issue presented is whether this court shall order forced medication to an involuntarily committed patient.
B., a young adult, was arrested for atrocious assault and battery upon his three-year-old nephew, S.B. had been baby-sitting the child, who cried uncontrollably, concluded that the child had a devil, and struck him. While awaiting hearing on the charge in the county jail B. attempted suicide *233 and was involuntarily transferred to Trenton Psychiatric Hospital on January 14, 1977.
Subsequent civil commitment reviews found him to be a danger to himself and a continued course of treatment necessary for the patient. B. has remained in Trenton Psychiatric Hospital until the present time.
At a subsequent hearing on B.'s commitment, the treating physician sought the court's permission to administer a psychotropic drug. The trial judge, while ordering B.'s continued institutionalization, scheduled a separate hearing on the question of forced medication and invited a court-appointed psychiatrist to review the treatment program, interview the patient and report to the court on the medication issue.
The treating physician testified that the use of psychotropic drugs was required because B. had not responded to all conventional therapies. Psychotropics is the name given to a group of drugs utilized by professionals to reduce a patient's psychotic symptoms and allow the hospitalized patient's return to and maintenance in the community. The doctor's drug of choice was Prolixin because of its benefits, and since it is administered by injection only once every two weeks, it avoids a need for the patient to be disturbed more often. He indicated that the hospital had repeatedly sought B.'s voluntary cooperation in using such medication without success.
B.'s reluctance derives from his own experiences with Haldol, another psychotropic drug, and his observations of Trenton Hospital inmates who take Prolixin. When B. earlier received Haldol, he said he slept up to 20 hours a day. The medical literature describes excessive drowsiness as a relatively common side effect of Haldol and other psychotropic drugs. B. also testified that many patients who receive Prolixin at Trenton Hospital display disturbing side effects. Prolixin and Haldol are two of a group of major tranquilizers affecting the central nervous system which are used in the treatment of schizophrenia. In a significant percentage of *234 patients, psychotropic drugs are known to produce effects similar to the symptoms of Parkinson's Disease, such as loss of muscular control, involuntary grimaces and twitching, among other symptomatology. While such symptoms are temporary in most cases and are controlled by anti-Parkinsonian drugs, the effects are sometimes permanent and known as tardive dyskinesia, a neurologic disorder. American College of Neuropsychopharmacology FDA Task Force, "Neurologic Syndromes Associated with Anti-Psychotic Drug Use", 289 N. Eng. J. Med. 20 (1973). B.'s reservations are fully shared by some commentators. See, e.g., Zander, "Prolixin Decanoate: A Review of the Research," 2 Mental Disability L.R. 37 (1977); DuBose, "Of the Parens Patriae Commitment Power and Drug Treatment of Schizophrenia: Do the Benefits to the Patient Justify Involuntary Treatment?," 60 Minn. L. Rev. 1149 (1976); Gardos et al., "Maintenance Antipsychotic Therapy: Is the Cure Worse than the Disease?" 133 Am. J. Psychiatry 32 (1976); Note, "Conditioning and Other Technologies Used to `Treat?' `Rehabilitate?' `Demolish?' Prisoners and Mental Patients," 45 S. Cal. L. Rev. 616 (1972).
The court finds the patient's refusal to take Prolixin is not, however, based entirely on rational considerations, but reflects delusional thinking. B.'s condition has been diagnosed as paranoid schizophrenia. He apparently hears voices, which he believes to be God's and which he obeys. On one occasion those voices directed him to assault another inmate. The inmate was evidently not harmed, and he and B. are now said to be friends. According to Dr. Sadoff, the court-appointed expert with excellent qualification, B. feels he must remain alert and strong in order to ward off evil forces. Dr. Sadoff recommended the voluntary ingestion of a psychotropic, Mellaril, to be forced upon B. only as a final alternative.
At a subsequent hearing on November 11, 1977, B. was found by another county court judge to be competent to stand criminal trial on the original atrocious assault and battery *235 charge, but not guilty of that offense by reason of insanity at the time it was committed.
In Price v. Sheppard, 239 N.W.2d 905, 911 (1976), the Minnesota Supreme Court held that an involuntarily committed mental patient may not withhold his consent to "customary" forms of treatment, stating: "If that interest of the state is sufficiently important to deprive an individual of his physical liberty, it would seem to follow that it would be sufficiently important for the state to assume the treatment decision. We hold that it is." The court went on to state, however, that federal constitutional law requires the informed consent of the patient or his guardian to "more intrusive forms of treatment." The court did not consider, however, whether administration of psychotropic medication is an intrusive form of treatment, and the Minnesota trial courts have divided over the question.
In In re Cleo Lundquist, No. 140151 (April 30, 1976), the Ramsey County, Minnesota Probate Court made these findings of fact:
1. That the use of Prolixin decanoate is an intrusive form of psychiatric treatment which requires the consent of the patient, or the consent of the patient's guardian, or an Order of the Court authorizing the treatment.
2. That the use of Prolixin decanoate may produce significant adverse side effects depending on the reaction of the patient to the drug and the amount of the drug injected into the patient's body. That the risk of adverse side effects is substantial when high dosages are used. When low dosages of 25 milligrams or less are used at intervals of not less than two weeks, the side effects are much less and can usually be controlled by other medication.
3. That Prolixin decanoate is not considered an experimental drug and has been approved by the Federal Drug Administration. However, its long-term effects at this time are unknown. That the use of the drug is a substantial intrusion into the patient's body although little pain is connected with treatment. That effects of the drug once injected into the body may produce changes in the patient's mental process lasting from four to eight weeks. That once injected into the body there is no known drug that can be used to counteract the effects of Prolixin decanoate.
*236 In In re Paul Fussa, No. 46912 (June 14, 1976), however, the Hennepin County, Minnesota Probate Court held the use of Prolixin to be a commonly employed medical practice.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
383 A.2d 760, 156 N.J. Super. 231, 1977 N.J. Super. LEXIS 1243, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-hospitalization-of-b-njsuperctappdiv-1977.